Neuropeptides and Alzheimer's disease pathology

Annals of the New York Academy of Sciences

Volumn 814, Issue , 1997, Pages 17-29

  Bissette, Garth ^a  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN PROTEIN; CORTICOTROPIN RELEASING FACTOR; NEUROPEPTIDE; NEUROTRANSMITTER; SOMATOSTATIN;

ALZHEIMER DISEASE; BRAIN LEVEL; BRAIN REGION; CONFERENCE PAPER; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; NEUROTRANSMITTER RELEASE;

EID: 0031010856     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.1997.tb46141.x     Document Type: Conference Paper

References (72)

1. FRANCIS, P. T., D. M. BOWEN, S. L. LOWE, D. NEARY, D. M. A. MANN & J. S. SNOWDEN. 1987. Somatostatin content and release measured in cerebral biopsies from demented patients. J. Neurol. Sci. 78: 1-16.
2. MANAYE, K. F., D. D. MCINTIRE, D. M. A. MANN & D. C. GERMAN. 1995. Locus coeruleus cell loss in the aging human brain: A non-random process. J. Comp. Neurol. 358: 79-87.
3. GEULA, C. & M.-M. MESULAM. 1994. Cholinergic systems and related neuropathological predilection patterns in Alzheimer disease. In Alzheimer Disease. R. D. Terry, R. Katzman & K. L. Bick, Eds.: 263-291. Raven Press. New York.
4. DAVIES, P. & A. J. F. MALONEY. 1976. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 2: 1403.
5. SLOTKIN, T. A., F. J. SEIDLER, B. J. CRAIN, J. M. BELL, G. BISSETTE & C. B. NEMEROFF. 1990. Regulatory changes in presynaptic cholinergic function assessed in rapid autopsy material from patients with Alzheimers disease: Implications for etiology and therapy. Proc. Natl. Acad. Sci. USA 87: 2452-2455.
6. AUBERT, I., D. M. ARAUJO, D. CÉCYRE, Y. ROBITAILLE, S. GAUTHIER & R. QUIRION. 1992. Comparative alterations of nicotinic and muscarinic binding sites in Alzheimer's and Parkinson's disease. J. Neurochem. 58: 529-541.
7. SVENSSON, A.-L., I. ALAFUZOFF & A. NORDBERG. 1992. Characterization of muscarinic receptor subtypes in Alzheimer and control brain cortices by selective muscarinic antagonists. Brain Res. 596: 142-148.
8. MESULAM, M.-M., C. GEULA & M. A. MORÁN. 1987. Anatomy of cholinesterase inhibition in Alzheimer's disease: Effect of physostigmine and tetrahydroaminoacridine on plaques and tangles. Ann. Neurol. 22: 683-691.
9. SOARES, J. C. & S. GERSHON. 1995. THA - Historical aspects, review of pharmacological properties and therapeutic effects. Dementia 6: 225-234.
10. ALLEN, N. H. P. & A. BURNS. 1995. The treatment of Alzheimer's disease. J. Psychopharmacol. 9: 43-56.
11. WHITEHOUSE, P. J. 1988. Intraventricular bethanecol in Alzheimer's disease: A continuing controversy. Neurology 38: 307-308.
12. GIACOBINI, E. 1994. Cholinomimetic therapy of Alzheimer disease: Does it slow down deterioration? In Recent Advances in the Treatment of Neurodegenerative Disorders and Cognitive Dysfunction. G. Racagni, N. Brunello & S. Z. Langer, Eds.: 51-57. Karger. Basel.
13. TRAUB, M. & S. B. FREEDMAN. 1992. The implication of current therapeutic approaches for the cholinergic hypothesis of dementia. Dementia 3: 189-193.
14. LEE, C.-M., P. C. EMSON & L. L. IVERSEN. 1981. Chromatographic behaviour and post-mortem stability of somatostatin in the rat and mouse brain. Brain Res. 220: 159-166.
15. EPELBAUM, J., P. DOURNAUD, M. FODOR & C. VIOLLET. 1994. The neurobiology of somatostatin. Crit. Rev. Neurobiol. 8: 25-44.
16. BISSETTE, G. & B. MYERS. 1992. Somatostatin in Alzheimer's disease and depression. Life Sci. 51: 1389-1410.
17. VÉCSAI, L. & P. KLIVÉNYI. 1995. Somatostatin and Alzheimer's disease. Arch. Gerontol. Geriatr. 21: 35-41.
18. GABRIEL, S. M., M. DAVIDSON, V. HAROUTUNIAN, P. POWCHIK, L. M. BIERER, D. P. PUROHIT, D. P. PERL & K. L. DAVIS. 1996. Neuropeptide deficits in schizophrenia vs. Alzheimer's disease cerebral cortex. Biol. Psychiatry 39: 82-91.
19. MAZUREK, M. F. & M. F. BEAL. 1991. Cholecystokinin and somatostatin in Alzheimer's disease postmortem cerebral cortex. Neurology 41: 716-719.
20. DAVIES, C. A., D. R. MORROLL, D. PRINJA, D. M. A. MANN & A. GIBBS. 1990. A quantitative assessment of somatostatin-like and neuropeptide Y-like immunostained cells in the frontal and temporal cortices of patients with Alzheimer's disease. J. Neurol. Sci. 96: 59-73.
21. GABRIEL, S. M., L. M. BIERER, V. M. HAROUTUNIAN, D. P. PUROHIT, D. P. PERL & K. L. DAVIS. 1993. Widespread deficits in somatostatin but not neuropeptide Y concentrations in Alzheimer's disease cerebral cortex. Neurosci. Lett. 155: 116-120.
22. ANG, L.-C. & D. D. SHUL. 1995. Peptidergic neurons of subcortical white matter in aging and Alzheimer's brain. Brain Res. 674: 329-335.
23. GASPAR, P., C. DUYCKAERTS, A. FEBVRET, R. BENOIT, B. BEEK & B. BERGER. 1989. Subpopulations of somatostatin 28-immunoreactive neurons display different vulnerability in senile dementia of the Alzheimer type. Brain Res. 490: 1-13.
24. DOURNAUD, P., P. CERVERA-PIEROT, E. HIRSCH, F. JAVOY-AGID, C. KORDON, Y. AGID & J. EPELBAUM. 1994. Somatostatin messenger RNA-containing neurons in Alzheimer's disease: An in situ hybridization study in hippocampus, parahippocampal cortex and frontal cortex. Neuroscience 61: 755-764.
25. GOMEZ, S., J. PUYMIRAT, P. VALADE, P. DAVOUS, P. RONDOT & P. COHEN. 1986. Patients with Alzheimer's disease show an increased content of 15K-dalton somatostatin precursor and a lowered level of tetradecapeptide in their cerebrospinal fluid. Life Sci. 39: 623-627.
26. YASUDA, M., K. MAEDA, T. KAKIGI, N. MINAMITANI, T. KAWAGUCHI & C. TANAKA. 1995. Low cerebrospinal fluid concentrations of peptide histidine valine and somatostatin-28 in Alzheimer's disease: Altered processing of prepro-vasoactive intestinal peptide and prepro-somatostatin. Neuropeptides 29: 325-330.
27. BEAL, M. F., M. F. MAZUREK, V. T. TRAN, G. CHATTA, E. D. BIRD & J. B. MARTIN. 1985. Reduced numbers of somatostatin receptors in the cerebral cortex in Alzheimer's disease. Science 229: 289-291.
28. 1 receptor sub-type in frontal and temporal cortices in Alzheimer's disease. Brain Res. 573: 299-304.
29. BERGSTRÖM, L., A. GARLIND, L. NILSSON, I. ALAFUZOFF, C. J. FOWLER, B. WINGBLAD & R. F. COWBURN. 1991. Regional distribution of somatostatin receptor binding and modulation of adenylyl cyclase activity in Alzheimer's disease brain. J. Neurol. Sci. 105: 225-233.
30. WEBER, S. J., R. B. LOUIS, L. TROMBLEY, G. BISSETTE, P. DAVIES & T. P. DAVIS. 1992. Metabolic half-life of somatostatin and peptidase activities are altered in Alzheimer's disease. J. Gerontol. 47: B18-25.
31. MOURADIAN, M. M., J. BLIN, M. GIUFFRA, I. J. HEUSER, F. BARONTINI, J. OWNBY & T. N. CHASE. 1991. Somatostatin replacement therapy for Alzheimer dementia. Ann. Neurol. 30: 610-613.
32. KARLSSON, I., E. WIDERLOV, E. V. MELIN, A.-L. NYTH, G. A. M. BRANE, E. RYBO, J. F. REHFELD, G. BISSETTE & C. B. NEMEROFF. 1985. Changes in CSF neuropeptides after environmental stimulation in dementia. Nord. Psychiatr. J. 39: 75-81.
33. WIDERLÖV, E., G. BRÅNE, R. EKMAN, M. KIHLGREN, A. NORBERG & I. KARLSSON. 1989. Elevated CSF somatostatin concentrations in demented patients parallel improved psychomotor functions induced by integrity-promoting care. Acta Psychiatr. Scand. 79: 41-47.
34. ALHAINEN, K., J. SIRVIÖ, E.-L. HELKALA, K. REINIKAINEN & P. REIKKINEN. 1991. Somatostatin and cognitive functions in Alzheimer's disease - The relationship of cerebrospinal fluid somatostatin increase with clinical response to tetrahydroaminoacridine. Neurosci. Lett. 130: 46-48.
35. KOPONEN, H., K. REINIKAINEN & P. J. REIKKINEN. 1990. Cerebrospinal fluid somatostatin in delirium. II. Changes at the acute stage and at one year follow-up. Psychol. Med. 20: 501-505.
36. NEMEROFF, C. B., E. WIDERLOV, G. BISSETTE, H. WALLEUS, I. KARLSSON, K. EKLUND, C. D. KILTS, P. T. LOOSEN & W. W. VALE. 1984. Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patients. Science 226: 1342-1344.
37. 1 receptor mRNA expression. J. Neurosci. 15: 6340-6350.
38. LOVENBERG, T. W., C. W. LIAW, D. E. GRIGORIADIS, W. CLEVENGER, D. T. CHALMERS, E. B. DESOUZA & T. OLTERSDORF. 1995. Cloning and characterization of a functionally distinct corticotropin-releasing factor receptor subtype from rat brain. Proc. Natl. Acad. Sci. USA 92: 836-840.
39. BISSETTE, G., G. P. REYNOLDS, C. D. KILTS, E. WIDERLÖV & C. B. NEMEROFF. 1985. Corticotropin-releasing factor-like immunoreactivity in senile dementia of the Alzheimer type. J. Am. Med. Assoc. 254: 3067-3069.
40. DESOUZA, E. B., P. J. WHITEHOUSE, M. J. KUHAR, D. L. PRICE & W. W. VALE. 1986. Reciprocal changes in corticotropin-releasing factor (CRF)-like immunoreactivity and CRF receptors in cerebral cortex of Alzheimer's disease. Nature 319: 593-595.
41. GRIGORIADIS, D. E., R. G. STRUBLE, D. L. PRICE & E. B. DESOUZA. 1989. Normal pattern of labeling of cerebral cortical corticotropin-releasing factor (CRF) receptors in Alzheimer's disease: Evidence from chemical crosslinking studies. Neuropharmacology 28: 761-764.
42. POWERS, R. E., L. C. WALKER, E. B. DESOUZA, W. W. VALE, R. G. STRUBLE, P. J. WHITEHOUSE & D. J. PRICE. 1987. Immunohistochemical study of neurons containing corticotropin-releasing factor in Alzheimer's disease. Synapse 1: 405-410.
43. KELLEY, M. & N. KOWALL. 1989. Corticotropin-releasing factor immunoreactive neurons persist throughout the brain in Alzheimers disease. Brain Res. 501: 392-396.
44. HARTZINGER, M., A. Z'BRUN, U. HEMMETER, E. SEIFRITZ, F. BAUMANN, E. HOLSBOER-TRACHSLER & I. J. HEUSER. 1995. Hypothalamic-pituitary-adrenal system function in patients with Alzheimer's disease. Neurobiol. Aging 16: 205-209.
45. RAADSHEER, F. C., J. J. VAN HEERIKHUIZE, P. J. LUCASSEN, W. J. G. HOOGENDIJK, F. J. H. TILDERS & D. F. SWAAB. 1995. Corticotropin-releasing hormone mRNA levels in the paraventricular nucleus of patients with Alzheimer's disease and depression. Am. J. Psychiatry 152: 1372-1376.
46. MARTIGNONI, E., F. PETRAGLIA, A. COSTA, G. BONO, A. R. GENAZZANI & G. NAPPI. 1990. Dementia of the Alzheimer type and the hypothalamus-pituitary-adrenocortical axis: Changes in cerebrospinal fluid corticotropin-releasing factor and plasma cortisol levels. Acta Neurol. Scand. 81: 452-456.
47. MOLCHAN, S. E., J. L. HILL, R. A. MARTINEZ, B. A. LAWLOR, A. M. MELLOW, D. R. RUBINOW, G. BISSETTE, C. B. NEMEROFF & T. SUNDERLAND. 1993. CSF somatostatin in Alzheimer's disease and major depression: Relationship to hypothalamic-pituitary-adrenal axis and clinical measures. Psychoneuroendocrinology 18: 509-519.
48. POMARA, N., R. R. SINGH, D. DEPTULA, P. A. LEWITT, G. BISSETTE, M. STANLEY & C. B. NEMEROFF. 1989. CSF corticotropin-releasing factor (CRF) in Alzheimer's disease: Its relationship to severity of dementia and monoamine metabolites. Biol. Psychiatry 26: 500-504.
49. JOLKKONEN, J., R. SOIKKELI, P. HARTIKAINEN, G. BISSETTE & P. REIKKINEN. 1990. CSF neuropeptides in Alzheimer's disease and Parkinson's disease. Anu. Psiquiatrico 1: 251-257.
50. EDVINSSON, L., L. MINTHON, R. EKMAN & L. GUSTAFSON. 1993. Neuropeptides in cerebrospinal fluid of patients with Alzheimer's disease and dementia with frontotem-poral lobe degeneration. Dementia 4: 167-171.
51. BANKI, C., L. KARMACSI, G. BISSETTE & C. B. NEMEROFF. 1992. Cerebrospinal neuropeptides in dementia. Biol. Psychiatry 32: 452-456.
52. HEILIG, M., M. SJÖGREN, K. BLENNOW, R. EKMAN & A. WALLIN. 1995. Cerebrospinal fluid neuropeptides in Alzheimer's disease and vascular dementia. Biol. Psychiatry 38: 210-216.
53. MAY, C., S. I. RAPOPORT, T. P. TOMAI, G. P. CHROUSOS & P. W. GOLD. 1987. Cerebrospinal fluid concentrations of corticotropin-releasing hormone (CRH) and corticotropin (ACTH) are reduced in Alzheimer's disease. Neurology 37: 535-538.
54. MOURADIAN, M. M., J. M. FARAH, E. MOHR, G. FABBRINI, T. L. O'DONOHUE & T. N. CHASE. 1986. Spinal fluid CRF reduction in Alzheimer's disease. Neuropeptides 8: 393-400.
55. SUEMARU, S., K. HASHIMOTO, T. OGASA, R. HIRASAWA, S. MAKINO, Z. OTA, J. KAGEYAMA & K. SUEMARU. 1991. Cerebrospinal fluid and plasma corticotropin-releasing hormone in senile dementia. Life Sci. 48: 1871-1879.
56. SUEMARU, S., K. SUEMARU, K. KAWAI, S. MIYATA, K. NOBUKINI, Y. THARA, R. NAMBA, K. URAKAMI & K. HASHIMOTO. 1995. Cerebrospinal fluid corticotropin-releasing hormone in neurodegenerative diseases: Reduction in spinocerebellar degeneration. Life Sci. 57: 2231-2235.
57. BEHAN, D. P., S. C. HEINRICHS, J. C. TRONCOSO, X-J. LIU, C. H. KAWAS, N. LING & E. B. DESOUZA. 1995. Displacement of corticotropin-releasing factor from its binding protein as a possible treatment for Alzheimer's disease. Nature 378: 284-287.
58. NEMEROFF, C. B., J. S. KIZER, G. P. REYNOLDS & G. BISSETTE. 1989. Neuropeptides in Alzheimer's disease: A postmortem study. Regul. Pept. 25: 123-130.
59. LEAKE, A., E. K. PERRY, R. H. PERRY, S. JABEEN, A. F. FAIRBAIRN, I. G. MCKEITH & I. N. FERRIER. 1991. Neocortical concentrations of neuropeptides in senile dementia of the Alzheimer and Lewy body type. Biol. Psychiatry 29: 357-364.
60. JOLKONNEN, J., P. HARTIKAINEN, R. SOIKKELI, G. BISSETTE, C. B. NEMEROFF & P. REIKKINEN. 1991. A correlation study of CSF neuropeptides in Alzheimer's and Parkinson's disease. Neuropeptides 19: 97-102.
61. TAMMINGA, C. A., N. L. FOSTER, P. FEDIO, E. D. BIRD & T. N. CHASE. 1987. Alzheimer's disease: Low cerebral somatostatin levels correlate with impaired cognitive function and cortical metabolism. Neurology 37: 161-165.
62. BIERER, L. M., V. HAROUTUNIAN, S. M. GABRIEL, P. J. KNOTT, L. S. CARLIN, D. P. PUROHIT, D. P. PERL, J. SCHMEIDLER, P. KANOF & K. L. DAVIS. 1995. Neurochemical correlates of dementia severity in Alzheimer's disease: Relative importance of the cholinergic deficits. J. Neurochem. 64: 749-760.
63. DORNAUD, P., P. DELAERE, J. J. HAUW & J. EPELBAUM. 1995. Differential correlation between neurochemical deficits, neuropathology and cognitive status in Alzheimer's disease. Neurobiol. Aging 16: 817-823.
64. ARENDASH, G. W., W. J. MILLARD, R. DAWSON, A. J. DUNN & E. M. MEYER. 1990. Different long-term effects of bilateral and unilateral nucleus basalis lesions on rat cerebral cortical neurotransmitter content. Neurochem. Res. 14: 1113-1118.
65. GAYKEMA, R. P. A., J. C. COMPAAN, C. NYAKAS, E. HORVATH & P. G. M. LUITEN. 1989. Long-term effects of cholinergic basal forebrain lesions on neuropeptide Y and somatostatin immunoreactivity in rat neocortex. Brain Res. 489: 392-396.
66. UNGER, J. W. & Y. SCHMIDT. 1994. Neuropeptide Y and somatostatin in the neocortex of young and aging rats: Response to nucleus basalis lesions. J. Clin. Neuroanat. 7: 25-34.
67. MILLARD, W. J., G. W. ARENDASH, A. J. DUNN & E. M. MEYER. 1990. Effects of nucleus basalis lesions on cerebral cortical concentrations of corticotropin-releasing hormone (CRH)-like immunoreactivity in the rat. Neurosci. Lett. 113: 233-239.
68. MOYSE, E., E. SZIGETHY, J. M. DANGER, H. VAUDRY, G. L. WENK, A. BEAUDET & J. EPELBAUM. 1993. Short- and long-term effects of nucleus basalis magnocellularis lesions on cortical levels of somatostatin and its receptors in the rat. Brain Res. 607: 154-160.
69. GOMEZ, S., P. DAVOUS, P. RONDOT, A. FAIVRE-BAUMAN, D. VALADE & J. PUYMIRAT. 1986. Somatostatin immunoreactivity and acetylcholinesterase activities in cerebrospinal fluid of patients with Alzheimer disease and senile dementia of the Alzheimer type. Psychoneuroendocrinology 11: 69-73.
70. URAKAMI, K., Y. ADACHI, E. AWAKI & K. TAKAHASHI. 1989. Characterization of the course of senile dementia of the Alzheimer type using cerebrospinal fluid levels of acetylcholinesterase and somatostatin. Acta Psychiatr. Scand. 80: 232-237.
71. REIMAN, E. M., R. J. CASSELL, L. S. YUN, K. CHEN, D. BANDY, S. MINOSHIMA, S. N. THIBODEAU & D. OSBORN. 1996. Preclinical evidence of Alzheimer's disease in persons homozygous for the e4 allele for apolipoprotein E. N. Engl. J. Med. 334: 752-758.
72. TERRY, R. D., E. MASLIAH, D. P. SALMON, N. BUTTERS, R. DETERESA, R. HILL, L. A. HANSEN & J. R. KATZMAN. 1991. Physical basis of cognitive alterations in Alzheimer's disease: Synapse loss is the major correlate of cognitive impairment. Ann. Neurol. 30: 572-580.